



ASX Announcement

BOARD AND MANAGEMENT SHARES PURCHASES AND APPENDICES 3Y

27 March 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) announces today the purchase of additional shares in the Company by key members of the Board of Directors and management team.

A summary of the purchases of Class A Common Stock is as follows:

- The Company's Chair and CEO, Steve Wedan, purchased 175,000 shares of Imricor Class A Common Stock, representing 175,000 CHESS Depositary Interests (CDIs);
- Imricor's Deputy Chair and Lead Independent Director, Mark Tibbles, purchased 175,000 shares of Imricor Class A Common Stock representing 175,000 CDIs;
- Two additional members of Imricor's management team purchased a combined 115,000 shares of Imricor Class A Common Stock, representing 115,000 CDIs.

All share purchases were completed off-market.

Mr Wedan, Mr Tibbles, and Imricor management are currently unable to purchase CDIs on-market due to the foreign restriction which precludes US citizens from purchasing CDIs.

Imricor's Chair and CEO, Steve Wedan, stated: "These share purchases underscore the strong belief we have in Imricor's mission to change the standard of care for cardiac catheter ablation and other interventions, and the confidence in our outstanding team, who continue to progress our strategic goals and position us for success."

Appendices 3Y for Mr Wedan and Mr Tibbles are annexed to this ASX announcement.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.



Further Information

Investors:

Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Investors & Australian Media:

Brett Ward
Senior Advisor, Cato & Clive
Email: brett@catoandclive.com
Mobile: +61 437 994 451

Rest of World Media:

Nick Twohy
Vice President of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407

Investors (Australia):

Aisha Jabeen
Advisor, Cato & Clive
Email: aisha@catoandclive.com
Phone: +61 430 563 964

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imricor Medical Systems, Inc.
ARBN	633 106 019

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Steve Wedan
Date of last notice	13 May 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Pensco Trust Company LLC on behalf of Steve Wedan - 478,640 shares of Class A common stock (equivalent to 478,640 CHES Depositary Interests).
Date of change	24 March 2022

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<ul style="list-style-type: none"> - 3,946,093 shares of Class A common stock, 1,427,373 Shares out of which are held jointly with his wife, Cherri Wedan (equivalent to 3,946,093 CHESS Depositary Interests) - 478,640 shares of Class A common stock (equivalent to 478,640 CHESS Depositary Interests) - 1,060,800 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 200,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 579,187 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 304,254 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Class	See above
Number acquired	175,000 shares of Class A common stock (equivalent to 175,000 CHESS Depositary Interests)
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	US\$0.29 per share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> - 4,121,093 shares of Class A common stock, 1,427,373 Shares out of which are held jointly with his wife, Cherri Wedan (equivalent to 4,121,093 CHESSE Depositary Interests). - 478,640 shares of Class A common stock (equivalent to 478,640 CHESSE Depositary Interests) - 1,060,800 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 200,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 579,187 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 304,254 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market trade.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	17 March 2022

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imricor Medical Systems, Inc.
ARBN	633 106 019

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Mark Tibbles
Date of last notice	13 May 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Citicorp Nominees Pty Limited is the registered holder for 2,111,573 CDIs held on behalf of Mr Tibbles.
Date of change	24 March 2022

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<ul style="list-style-type: none"> - 2,440,305 shares of Class A common stock (equivalent to 2,440,305 CHESS Depositary Interests) - 2,141,573 CHESS Depositary Interests (equivalent to 2,141,573 shares of Class A common stock) - 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 100,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 71,010 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 40,896 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Class	See above
Number acquired	175,000 shares of Class A common stock (equivalent to 175,000 CHESS Depositary Interests)
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	US\$0.29 per share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> - 2,615,305 shares of Class A common stock (equivalent to 2,615,305 CHESS Depositary Interests) - 2,141,573 CHESS Depositary Interests (equivalent to 2,141,573 shares of Class A common stock) - 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 100,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 71,010 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 40,896 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	17 March 2022

⁺ See chapter 19 for defined terms.